Extended storage of SARS-CoV-2 nasopharyngeal swabs does not negatively impact results of molecular-based testing across three clinical platforms

Karin A. Skalina, D. Y. Goldstein, Jaffar Sulail, Eunkyu Hahm, Momka Narlieva, Wendy Szymczak, Amy S. Fox

Research output: Contribution to journalArticlepeer-review

15 Scopus citations

Abstract

With the global outbreak of COVID-19, the demand for testing rapidly increased and quickly exceeded the testing capacities of many laboratories. Clinical tests which receive CE (Conformité Européenne) and Food and Drug Administration (FDA) authorisations cannot always be tested thoroughly in a real-world environment. Here we demonstrate the long-Term stability of nasopharyngeal swab specimens for SARS-CoV-2 molecular testing across three assays recently approved by the US FDA under Emergency Use Authorization. This study demonstrates that nasopharyngeal swab specimens can be stored under refrigeration or even ambient conditions for 21 days without clinically impacting the results of the real-Time reverse transcriptase-PCR testing.

Original languageEnglish (US)
Pages (from-to)61-64
Number of pages4
JournalJournal of Clinical Pathology
Volume75
Issue number1
DOIs
StatePublished - Jan 1 2022

Keywords

  • hospital
  • microbiology
  • pathology department
  • polymerase chain reaction
  • virology

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Fingerprint

Dive into the research topics of 'Extended storage of SARS-CoV-2 nasopharyngeal swabs does not negatively impact results of molecular-based testing across three clinical platforms'. Together they form a unique fingerprint.

Cite this